Abstract Background Direct oral anticoagulants (DOACs) are widely used for the treatment of
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …

Introduction: Direct oral anticoagulants (DOACs) have overtaken warfarin in the treatment of
nonvalvular atrial fibrillation (AF) and venous thromboembolism (VTE). Limited data explore …

Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …

Background Atrial fibrillation and heart failure are combined risk factors for thromboembolic
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …

Introduction Patients with atrial fibrillation (AF) should be prescribed standard-dose (5mg
twice daily) apixaban for stroke prevention unless they meet 2 or more criteria: age≥ 80 …

There is limited knowledge regarding the efficacy and safety of fixed-dose oral
anticoagulants in overweight patients because of the possible increased risk of embolism …

Background: Apixaban is commonly used to prevent stroke in older adults with nonvalvular
atrial fibrillation (AF). Although its package insert has specific dose reduction criteria …

Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …

Apixaban is a direct oral anticoagulant used as a first-line therapy for the prevention of
systemic thromboembolism in patients with atrial fibrillation. In the ARISTOTLE trial …

Background Limited data exist on the safety and effectiveness of using direct oral
anticoagulants (DOACs) in patients with atrial fibrillation aged 80 years or more with and …